Huadong Medicine Co., Ltd (SHE:000963)
China · Delayed Price · Currency is CNY 29.93
+0.30 (1.01%)
Aug 11, 2026, 2:25 PM CST
Huadong Medicine Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 51,963 | 69,031 | 60,553 | 72,565 | 82,087 | 70,342 | |
Market Cap Growth | -30.08% | 14.00% | -16.55% | -11.60% | 16.70% | 51.35% |
Enterprise Value | 50,743 | 67,298 | 58,711 | 70,923 | 81,583 | 69,341 |
Last Close Price | 29.63 | 38.63 | 33.16 | 38.52 | 43.17 | 36.82 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 14.84 | 20.22 | 17.24 | 25.56 | 32.85 | 30.56 |
Forward PE | 11.56 | 18.98 | 19.83 | 27.57 | 30.39 | 29.34 |
PS Ratio | 1.18 | 1.58 | 1.45 | 1.79 | 2.18 | 2.04 |
PB Ratio | 1.99 | 2.74 | 2.57 | 3.36 | 4.28 | 4.15 |
P/TBV Ratio | 2.74 | 3.81 | 3.67 | 4.50 | 5.92 | 5.76 |
P/FCF Ratio | 17.17 | 25.84 | 29.96 | 31.24 | 69.06 | 29.92 |
P/OCF Ratio | 12.30 | 16.26 | 16.15 | 18.47 | 34.46 | 22.19 |
PEG Ratio | 1.26 | 1.62 | 1.33 | 1.49 | 0.60 | 0.60 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 1.15 | 1.54 | 1.40 | 1.75 | 2.16 | 2.01 |
EV/EBITDA Ratio | 9.82 | 13.34 | 11.50 | 16.43 | 21.60 | 20.91 |
EV/EBIT Ratio | 12.34 | 16.33 | 13.53 | 19.76 | 25.86 | 24.71 |
EV/FCF Ratio | 16.76 | 25.19 | 29.05 | 30.54 | 68.64 | 29.50 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.08 | 0.08 | 0.13 | 0.09 | 0.14 | 0.12 |
Debt / EBITDA Ratio | 0.42 | 0.41 | 0.58 | 0.44 | 0.67 | 0.61 |
Debt / FCF Ratio | 0.71 | 0.80 | 1.50 | 0.83 | 2.17 | 0.89 |
Net Debt / Equity Ratio | -0.06 | -0.12 | -0.09 | -0.13 | -0.07 | -0.11 |
Net Debt / EBITDA Ratio | -0.31 | -0.58 | -0.44 | -0.63 | -0.37 | -0.59 |
Net Debt / FCF Ratio | -0.52 | -1.10 | -1.11 | -1.17 | -1.19 | -0.83 |
Asset Turnover | 1.11 | 1.13 | 1.17 | 1.26 | 1.30 | 1.35 |
Inventory Turnover | 5.75 | 5.72 | 6.18 | 6.25 | 6.07 | 5.96 |
Quick Ratio | 1.21 | 1.15 | 1.15 | 1.28 | 1.23 | 1.21 |
Current Ratio | 1.67 | 1.62 | 1.53 | 1.71 | 1.73 | 1.67 |
Return on Equity (ROE) | 13.80% | 14.00% | 15.48% | 13.97% | 14.02% | 14.56% |
Return on Assets (ROA) | 6.48% | 6.70% | 7.60% | 6.94% | 6.78% | 6.85% |
Return on Invested Capital (ROIC) | 14.98% | 16.07% | 17.55% | 16.10% | 16.09% | 16.02% |
Return on Capital Employed (ROCE) | 15.30% | 15.90% | 18.00% | 15.80% | 15.00% | 15.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 6.74% | 4.95% | 5.80% | 3.91% | 3.04% | 3.27% |
FCF Yield | 5.83% | 3.87% | 3.34% | 3.20% | 1.45% | 3.34% |
Dividend Yield | 3.21% | 2.41% | 2.80% | 1.51% | 0.67% | 0.79% |
Payout Ratio | 48.88% | 49.56% | 48.47% | 20.93% | 23.07% | 19.99% |
Buyback Yield / Dilution | 0.02% | -0.06% | -0.08% | -0.10% | -0.00% | 0.00% |
Total Shareholder Return | 3.23% | 2.35% | 2.72% | 1.40% | 0.67% | 0.79% |